TABLE 4.
COVID-19 vaccine uptake and acceptability. (COVID-19 vaccination in health workers; Sierra Leone, Democratic Republic of Congo and Uganda; 2021).
| Kambia | Goma | Masaka | Total | |
|---|---|---|---|---|
| N = 124 | N = 188 | N = 231 | N = 543 | |
| COVID-19 vaccination status | ||||
| Fully vaccinated a , b | 9 (7.3) | 0 | 34 (14.7) | 43 (7.9) |
| Partially vaccinated a , b | 39 (31.5) | 0 | 55 (23.8) | 94 (17.3) |
| Unvaccinated—would accept vaccine | 75 (60.5) | 81 (43.1) | 136 (58.9) | 294 (53.9) |
| Unvaccinated—would not accept vaccine | 1 (0.8) | 91 (48.4) | 4 (1.7) | 96 (17.7) |
| Unvaccinated—unsure if would accept vaccine | 0 | 16 (8.5) | 2 (0.9) | 18 (3.3) |
| Reasons for accepting or being willing to accept the vaccine c , d | ||||
| To protect own health | 123 (99.2) | 81 (43.1) | 214 (92.6) | 418 (77.0) |
| To keep working | 122 (98.4) | 49 (26.1) | 100 (43.3) | 271 (49.9) |
| To avoid infecting other people | 123 (99.2) | 79 (42.0) | 161 (69.7) | 363 (66.9) |
| To protect family | 122 (98.4) | 76 (40.4) | 172 (74.5) | 370 (68.1) |
| Reasons for unwillingness to accept vaccine c , d | ||||
| Not at risk of catching SARS-CoV-2 | 1 (0.8) | 18 (9.6) | 2 (0.9) | 21 (3.9) |
| Not at risk of becoming very ill or dying from COVID-19 | 1 (0.8) | 18 (9.6) | 0 | 19 (3.5) |
| Already had COVID-19 | 0 | 2 (1.1) | 1 (0.4) | 3 (0.6) |
| Frightened of vaccine side effects | 1 (0.8) | 74 (39.4) | 5 (2.2) | 80 (14.7) |
| COVID-19 vaccines are new and experimental | 0 | 75 (39.9) | 6 (2.6) | 81 (14.9) |
| COVID-19 vaccines don’t work | 0 | 30 (16.0) | 2 (0.9) | 32 (5.9) |
| Currently pregnant/breastfeeding | 0 | 3 (1.6) | 0 | 3 (0.6) |
| Factors that would influence decision on whether to get vaccinated c , e | ||||
| Which country the vaccine was developed in | 100 (80.7) | 105 (55.9) | 129 (55.8) | 334 (61.5) |
| Which company made the vaccine | 92 (74.2) | 88 (46.8) | 100 (43.3) | 280 (51.6) |
| Where the clinical trials were conducted | 98 (79.0) | 138 (73.4) | 105 (45.5) | 341 (62.8) |
| Whether clinical trials were conducted here | 92 (74.2) | 118 (62.8) | 87 (37.7) | 297 (54.7) |
| How many people were vaccinated before | 91 (73.4) | 127 (67.6) | 73 (31.6) | 291 (53.6) |
| How long the vaccine had been trialled for | 110 (88.7) | 134 (71.3) | 111 (48.1) | 355 (65.4) |
| What type of vaccine it is | 85 (68.6) | 73 (38.8) | 109 (47.2) | 267 (49.2) |
| Which other countries are giving the vaccine | 55 (44.4) | 90 (47.9) | 72 (31.2) | 217 (40.0) |
N, number.
In Kambia, vaccination status was confirmed for all 48 vaccinated participants using vaccination cards. In Masaka, vaccination status was confirmed for 13 vaccinated participants using vaccination cards, and 76 participants reported that they were vaccinated verbally.
79.6% of participants who received at least one vaccine dose were given the AstraZeneca vaccine (50.0% in Kambia; 95.5% in Masaka). In Kambia, all other vaccinated participants received the Sinopharm vaccine; in Masaka, all other vaccinated participants received the Sinovac vaccine.
Participants could provide more than one answer so summed percentages are not equal to 100%.
Participants provided either reasons for or against vaccination as appropriate to their answer for the vaccination status variable above, but proportions were calculated as percentages of the whole study population (by country and across all countries).
Results are shown for all participants, including participants who had already received one or more COVID-19 vaccine doses.